BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuk HD, Lee KH, Lee HS, Jeong SH, Kho Y, Jeong CW, Kim HH, Ku JH, Kwak C. PDLIM2 Suppression Inhibit Proliferation and Metastasis in Kidney Cancer. Cancers (Basel) 2021;13:2991. [PMID: 34203785 DOI: 10.3390/cancers13122991] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu L, Schuetze R, Gerberich JL, Lopez R, Odutola SO, Tanpure RP, Charlton-Sevcik AK, Tidmore JK, Taylor EA, Kapur P, Hammers H, Trawick ML, Pinney KG, Mason RP. Demonstrating Tumor Vascular Disrupting Activity of the Small-Molecule Dihydronaphthalene Tubulin-Binding Agent OXi6196 as a Potential Therapeutic for Cancer Treatment. Cancers (Basel) 2022;14. [PMID: 36077745 DOI: 10.3390/cancers14174208] [Reference Citation Analysis]
2 Zeng Y, Lin D, Gao M, Du G, Cai Y. Systematic evaluation of the prognostic and immunological role of PDLIM2 across 33 cancer types. Sci Rep 2022;12:1933. [PMID: 35121770 DOI: 10.1038/s41598-022-05987-1] [Reference Citation Analysis]
3 Guo ZS, Qu Z. PDLIM2: Signaling pathways and functions in cancer suppression and host immunity. Biochim Biophys Acta Rev Cancer 2021;1876:188630. [PMID: 34571051 DOI: 10.1016/j.bbcan.2021.188630] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]